Investment analysts at First Analysis assumed coverage on shares of Catalent (NYSE:CTLT) in a research report issued to clients and investors on Friday, The Fly reports. The brokerage set an “equal weight” rating on the stock.
Several other research firms have also recently weighed in on CTLT. BidaskClub cut Catalent from a “buy” rating to a “hold” rating in a report on Tuesday, November 14th. Zacks Investment Research raised Catalent from a “hold” rating to a “strong-buy” rating and set a $49.00 price target on the stock in a report on Thursday, October 26th. ValuEngine raised Catalent from a “hold” rating to a “buy” rating in a report on Thursday, September 7th. Morgan Stanley raised Catalent from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $29.00 to $48.00 in a report on Thursday, September 21st. Finally, Needham & Company LLC reissued a “hold” rating on shares of Catalent in a report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company’s stock. Catalent presently has an average rating of “Hold” and a consensus target price of $44.44.
Shares of Catalent (NYSE:CTLT) traded down $0.57 on Friday, reaching $41.78. The company’s stock had a trading volume of 650,300 shares, compared to its average volume of 834,533. The stock has a market cap of $5,530.00, a P/E ratio of 48.58, a price-to-earnings-growth ratio of 2.72 and a beta of 1.41. The company has a current ratio of 2.91, a quick ratio of 2.49 and a debt-to-equity ratio of 2.01. Catalent has a 1-year low of $25.51 and a 1-year high of $43.39.
Catalent (NYSE:CTLT) last released its quarterly earnings results on Monday, November 6th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.01. The firm had revenue of $543.90 million for the quarter, compared to analysts’ expectations of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The company’s revenue was up 23.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.16 EPS. equities analysts expect that Catalent will post 1.46 earnings per share for the current fiscal year.
In related news, Director Uwe Roehrhoff bought 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were bought at an average cost of $39.22 per share, with a total value of $294,150.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider John R. Chiminski sold 181,458 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its stake in Catalent by 15.2% in the 2nd quarter. BlackRock Inc. now owns 17,512,661 shares of the company’s stock worth $614,695,000 after buying an additional 2,316,849 shares in the last quarter. Vanguard Group Inc. increased its stake in Catalent by 3.8% in the 2nd quarter. Vanguard Group Inc. now owns 10,119,431 shares of the company’s stock worth $355,192,000 after buying an additional 369,526 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in Catalent in the 2nd quarter worth $239,629,000. State Street Corp increased its stake in Catalent by 10.7% in the 2nd quarter. State Street Corp now owns 4,315,841 shares of the company’s stock worth $151,488,000 after buying an additional 418,196 shares in the last quarter. Finally, Earnest Partners LLC increased its stake in Catalent by 0.5% in the 3rd quarter. Earnest Partners LLC now owns 2,570,156 shares of the company’s stock worth $102,601,000 after buying an additional 12,652 shares in the last quarter. 99.37% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Catalent (CTLT) Now Covered by First Analysis” was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/05/catalent-ctlt-now-covered-by-first-analysis.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.